Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toreforant in active rheumatoid arthritis
NCT00941707Phase 2Terminated
- Sponsor
- Johnson & Johnson
- Start
- Feb 2010
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing JNJ-38518168 with Placebo (2 arms). Primary endpoint: Disease Activity Index Score 28 C-Reactive Protein at 12 weeks. Started Feb 2010; status: terminated.
02
Drugs
toreforant
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00941707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00941707.